DECN Well Ahead of Schedule, Decision Diagnostic's Pharma

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
DECN Well Ahead of Schedule, Decision Diagnostic's Pharma Tech Division Completes First Major Shipments of its Popular Genstrip Te...

genStrip sales powered by changes in medicare and private insurance reimbursements  moving demand away from mail order pharmacy models.
company to  focus on neighborhood pharmacies who can now ensure profit by servicing medicare patients who have lost mail order pharmacy service.
chain pharmacy and other large retailers looking to buy genstrip for retail sales and to add genstrip to service the medicare walk-in patients.
 

 

Los Angeles, CA, - (Accesswire - October 31, 2013 ) -  Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that beginning Friday October 25 and continuing every business day since, its Pharma Tech Solutions subsidiary has completed the first GenStrip bulk shipments to large box distributors of GenStrip, ahead of schedule, and in quantities greater than expected. More shipments are planned as soon as additional volume is available.

Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, "Beginning in July 2013, Medicare changed its reimbursement practice with a goal of lowering the cost of healthcare.  These changes have had the impact of moving the market away from mail order pharmacy fulfillment models, which have dominated the last decade, and back toward traditional brick and mortar pharmacies. The GenStrip business model works very well in the post July 2013environment and has provided us with an unexpected boom for our business."
DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. DECN's FDA cleared Shasta GenStrip(TM) product was first introduced to the market in late 2012 as a lower cost (50%) glucose test strip alternative for user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®, Ultra2(R) and Ultra Mini(R) glucose meters.
Mr. Berman concluded, "we also note that in August and September 2013 we received several favorable court rulings and our competition ended their practice of sending threatening letters to our customers.  Earlier this week we announced the receipt of a $12.5 million non-dilutive credit line, adding to the positive outlook for Genstrip sales by allowing us to grow to $250+ million in sales."  

The company also reminds shareholders and all interested parties that it continues to air its new commercial video titled "GenStrip: A Patchwork of Life." The company’s video will begin play today. As soon as the media company produces the complete media schedule, we will post this schedule on our Web Sites. In the meantime the extremely popular video  is available for viewing at: http://shastagenstrip.com/shasta_ad.html or http://youtu.be/zzBuHxb-rlM  
Forward-Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about Shasta GenStrip, please visit the company's Web Sites: http://www.decisiondiagnostics.com or http://www.shastagenstrip.com.
GenStrip(TM) test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan(R), Inc. a Johnson & Johnson(R) Company, manufacturers and distributors of the OneTouch(R) Ultra(R) Family of Meters and OneTouch(R) Ultra(R) test strips.
Contact:

Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon

Updated Category News Views 63

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon FRP Holdings, Inc. (NASDAQ: FRPH) is gearing up for an important update regarding their financial performance. The company is set to release its earnings results for the third quarter on an upcoming Wednesday. This announcement is keenly awaited by analysts and investors alike as it reflects the company's current...

Continue Reading
ACECO's Heartwarming Initiative Distributes Backpacks for Students

Updated Category News Views 126

ACECO Partners with United Way for Community Support In a remarkable effort to support local educational needs, ACECO has engaged its Hoist Up! Outreach Committee to collaborate with the United Way for the distribution of 250 backpacks filled with school supplies. This initiative demonstrates a strong commitment to helping students thrive as they return to school....

Continue Reading
Exploring Iovance Biotherapeutics' Recent Legal Challenges

Updated Category News Views 105

An Overview of Iovance Biotherapeutics Legal Issues Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has found itself in a challenging position following a recent class-action lawsuit. This situation has arisen due to allegations of securities fraud involving the company and its senior executives. The Class Action Lawsuit Explained The lawsuit, filed by a respected securities...

Continue Reading
Ross Gerber Offers Insightful Take on Tesla and Elon Musk

Updated Category News Views 154

Ross Gerber on His Views About Tesla and Elon Musk Ross Gerber openly shares his thoughts on the dynamic leadership of Elon Musk while at the same time being critical of some of the recent directions of Tesla. During a recent episode of the 'Chasing Finance' podcast, Gerber expressed his mixed feelings stating, “I’m not a fan of Elon.” However, he quickly added,...

Continue Reading
KLA Corporation Adjusts Price Target Yet Maintains Strong Outlook

Updated Category News Views 62

Revised Price Target and Market Insights for KLA Corporation KLA Corporation (NASDAQ: KLAC) has recently seen its stock target adjusted by Stifel to $800, down from $875. Despite this revision, the firm has retained a Buy rating for the company, reflecting confidence in its performance. Stifel noted that KLA exceeded expectations in its latest quarterly performance,...

Continue Reading